## Hirofumi Sawada

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1470679/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension. Journal of Clinical Investigation, 2013, 123, 3600-3613.	3.9	354
2	Reduced BMPR2 expression induces GM-CSF translation and macrophage recruitment in humans and mice to exacerbate pulmonary hypertension. Journal of Experimental Medicine, 2014, 211, 263-280.	4.2	123
3	A Nuclear Factor-κB Inhibitor Pyrrolidine Dithiocarbamate Ameliorates Pulmonary Hypertension in Rats. Chest, 2007, 132, 1265-1274.	0.4	90
4	Potential Contribution of Phenotypically Modulated Smooth Muscle Cells and Related Inflammation in the Development of Experimental Obstructive Pulmonary Vasculopathy in Rats. PLoS ONE, 2015, 10, e0118655.	1.1	31
5	The ALK-1/SMAD/ATOH8 axis attenuates hypoxic responses and protects against the development of pulmonary arterial hypertension. Science Signaling, 2019, 12, .	1.6	24
6	Macitentan reverses early obstructive pulmonary vasculopathy in rats: early intervention in overcoming the survivin-mediated resistance to apoptosis. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2015, 308, L523-L538.	1.3	22
7	Detection of Pediatric Pulmonary Arterial Hypertension by School Electrocardiography Mass Screening. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 1397-1406.	2.5	19
8	Effect of thrombomodulin on the development of monocrotaline-induced pulmonary hypertension. Journal of Anesthesia, 2014, 28, 26-33.	0.7	14
9	CRISPR-mediated Bmpr2 point mutation exacerbates late pulmonary vasculopathy and reduces survival in rats with experimental pulmonary hypertension. Respiratory Research, 2022, 23, 87.	1.4	3